Author: Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd.

Posted Date:

March 20, 2026

Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability

Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd.

March 20, 2026
Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs

Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd.

March 17, 2026
XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd.

March 1, 2026
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd.

February 24, 2026